Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc KHTRF


Primary Symbol: T.GUD

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by gudisgoodon Aug 10, 2023 4:01pm
110 Views
Post# 35582508

RE:RE:RE:Updated Outlook

RE:RE:RE:Updated OutlookI would also agree that it was a mixed bag of results. Revenue growth but lacking in profitability.

Fortunately a nice amount of submissions took place. Even an approval. The pipeline is moving forward although it would be nice to see more products added to it.

I'm sure they would like to onload more products to the platform as well. It's just that they will remain patient while looking for the deals that fit the strategy. Are they too demanding / should they lower the threshold? I don't know - the reason I'm invested here is because I trust them to know what they're doing. I believe the right deal(s) will come. We all (including the management) want to put the capital to work to reap the benefits of the platform, and to do that rather sooner than later. That $100+ million of cash should be working for us. But again, they will remain patient. Not everyone has the discipline precisely because during times like this, it would be easier to spend the money and make the deals just to do something. Sitting on your hands waiting for the right deal is difficult. I'm not saying the lack of new deals is a positive thing; I just mean it comes with the territory.

It's difficult to say if the BD team is underperforming. The outcomes vary but do they have the right process? Do they know what they're doing? Perhaps they're doing the right things and it's just a matter of running into the right opportunity. I trust the judgment of Goodman and Samira to determine whether the team is efficient.

I somewhat agree with your point about where the business is five years after the acquisition. Now, to be fair, Covid really slowed us down for a couple of years. So I'm not that worried about the profitability and the margins right now... but I do want to see the pipeline growing because that's mainly what's going to drive growth into the future. The point of having the platform is to keep adding new products to it.

The valuation landscape seems unchanged even though the macro environment has changed. That's interesting. Then again, it's never in the interest of the shareholders for them to say "we're seeing great deals out there." That could have a negative effect on the negotations. So we don't know what they're seeing out there. In any case, we don't necessarily need a great environment for deals... we just need a great deal.

Random:

Is there any significance to Jeff Martens no longer being on the call? According to Linkedin, he's still with the company. However, you cannot see him on the management team page over at KnightTX.com.
<< Previous
Bullboard Posts
Next >>